A Phase 2 interventional study of Levetiracetam in Absence Seizures, sponsored by UCB Pharma. Completed. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2013-09-17.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies testing levetiracetam in Seizures — 9 open to participants now, 9 under way, 5 of them phase 3. Levetiracetam · Seizures.
Among the 52 studies testing levetiracetam in Seizures, this one is the 49th largest by enrollment, is the only one that started in 2000, is one of 7 in phase 2, and was the 11th registered.
766 studies on the registry are indexed under Seizures; 134 are open to participants now.
Browse Seizures studies →9 of the 52 studies testing levetiracetam in Seizures are open now, in 6 countries. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 18–75
Ayal A. Aizer, MD · Sites in United States
Ages 18+
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 40+
All India Institute of Medical Sciences, Jodhpur · Sites in India
Ages 18–70
Ministry of Health and Sports, Myanmar · Sites in Burma
Ages 1 mo–12 yrs
By country, each count listing its studies:
Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.
This study: 4 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 20 · Phase 4 11
First in 2000; this study’s year is marked. 1 started in 2000.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4 is below the median of 64 across 519 interventional studies indexed under Seizures.
Median enrollment 68 across the 52 interventional studies. Of the 37 that completed or were terminated, 22 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 52 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
40 studies in Seizures by UCB S.A.: 3 open now, 4 under way, 4 of them phase 3. Of 36 finished, 31 (86%) have results posted.
Among the 40 studies in Seizures by UCB S.A., this one is the 35th largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2000, is one of 8 in phase 2, and was the 8th registered.
UCB S.A.’s Seizures studies by the year they started, since 2000.
2 of the studies testing levetiracetam in Seizures that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07239115Phase 3Beijing Tiantan HospitalLevetiracetam for Seizure Prevention After Brain Tumor Surgery | 2027-01 |
| NCT07072624All India Institute of Medical Sciences, JodhpurEarly Post-Traumatic Seizures Prevention Trial (E-PTS Trial) | 2027-03-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 52 studies testing levetiracetam in Seizures, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 40 in Seizures:
This tab as a report to print or save as PDF → With an account.
This long-term open label follow-up trial gave pediatric subjects suffering from typical absences in CAE or JAE the opportunity to continue levetiracetam treatment after participation in the pilot study (study N162) or the double-blind study (study N163). Safety and efficacy data were obtained.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Continue levetiracetam treatment after participation in the pilot-study N162 or in study N163; Assess long-term safety profile and efficacy of levetiracetam
No study locations are listed for this record.
The record gives a start of May 2000, a primary completion of May 2003 and a completion of May 2003. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levetiracetam